Sun may only get 3 of Ranbaxy's 4 banned plants ready for U.S. market

Ranbaxy Laboratories, which Sun Pharmaceutical recently acquired for $4 billion, has four plants in India that once produced products for the U.S. market. All four were banned by the FDA over the last 5 years for manufacturing and drug testing issues. But Sun may now only intend to spend the time and money to get three of them back to FDA standards, sources tell the Economic Times. They said the plant in Paonta Sahib, which is still producing products for other markets, may be used just for making drugs for use by the World Health Organization as well as for sale in Europe and Australia. Story | More

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.